76 related articles for article (PubMed ID: 7872061)
1. Pharmacokinetics of clodronate in renal failure.
Saha H; Castren-Kortekangas P; Ojanen S; Juhakoski A; Tuominen J; Tokola O; Pasternack A
J Bone Miner Res; 1994 Dec; 9(12):1953-8. PubMed ID: 7872061
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of disodium clodronate after daily intravenous infusions during five consecutive days.
Hanhijärvi H; Elomaa I; Karlsson M; Lauren L
Int J Clin Pharmacol Ther Toxicol; 1989 Dec; 27(12):602-6. PubMed ID: 2533182
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetics of clodronate after single and repeated doses.
Ylitalo P; Holli K; Mönkkönen J; Elo HA; Juhakoski A; Liukko-Sipi S; Ylitalo R
Int J Clin Pharmacol Ther; 1999 Jun; 37(6):294-300. PubMed ID: 10395121
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of nicotine in kidney failure.
Molander L; Hansson A; Lunell E; Alainentalo L; Hoffmann M; Larsson R
Clin Pharmacol Ther; 2000 Sep; 68(3):250-60. PubMed ID: 11014406
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of oral cefatrizine in patients with impaired renal function.
Couet W; Fauvel JP; Laville M; Pozet N; Fourtillan JB
Int J Clin Pharmacol Ther Toxicol; 1991 Jun; 29(6):213-7. PubMed ID: 1869342
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of clodronate in haemodialysis patients.
Ala-Houhala I; Saha H; Liukko-Sipi S; Ylitalo P; Pasternack A
Nephrol Dial Transplant; 1999 Mar; 14(3):699-705. PubMed ID: 10193822
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of incadronate, a new bisphosphonate, in healthy volunteers and patients with malignancy-associated hypercalcemia.
Usui T; Oiso Y; Tomita A; Ogata E; Uchida T; Ikeda K; Watanabe T; Higuchi S
Int J Clin Pharmacol Ther; 1997 Jun; 35(6):239-44. PubMed ID: 9208339
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of fleroxacin in renal impairment.
Weidekamm E
Am J Med; 1993 Mar; 94(3A):70S-74S. PubMed ID: 8452185
[TBL] [Abstract][Full Text] [Related]
11. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay.
Cheng JW; Charland SL; Shaw LM; Kobrin S; Goldfarb S; Stanek EJ; Spinler SA
Pharmacotherapy; 1997; 17(3):584-90. PubMed ID: 9165563
[TBL] [Abstract][Full Text] [Related]
12. Pentostatin pharmacokinetics and dosing recommendations in patients with mild renal impairment.
Lathia C; Fleming GF; Meyer M; Ratain MJ; Whitfield L
Cancer Chemother Pharmacol; 2002 Aug; 50(2):121-6. PubMed ID: 12172976
[TBL] [Abstract][Full Text] [Related]
13. Disposition kinetics of dibekacin in normal subjects and in patients with renal failure.
Arancibia A; Chávez J; Ibarra R; Ruiz I; Icarte A; Thambo S; Chávez H
Int J Clin Pharmacol Ther Toxicol; 1987 Jan; 25(1):38-43. PubMed ID: 3557728
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of ofloxacin in healthy subjects and patients with varying degrees of renal impairment.
Flor S; Guay D; Opsahl J; Tack K; Matzke G
Int J Clin Pharmacol Res; 1991; 11(3):115-21. PubMed ID: 1809697
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of clodronate in peritoneal dialysis patients.
Saha HH; Ala-Houhala IO; Liukko-Sipi SH; Ylitalo P; Pasternack AI
Perit Dial Int; 1998; 18(2):204-9. PubMed ID: 9576370
[TBL] [Abstract][Full Text] [Related]
17. Steady state pharmacokinetics and dose equivalents of oral clodronate in renal failure.
Mäkelä S; Saha H; Ala-Houhala I; Liukko-Sipi S; Ylitalo P
Int J Clin Pharmacol Ther; 2011 Feb; 49(2):128-36. PubMed ID: 21255529
[TBL] [Abstract][Full Text] [Related]
18. [Is endogenous creatinine clearance a sound basis for estimation of elimination half life of gentamicin?].
Rameis H; Hitzenberger G; Jaschek I; Graninger W
Dtsch Med Wochenschr; 1980 Nov; 105(47):1650-4. PubMed ID: 7439047
[TBL] [Abstract][Full Text] [Related]
19. A pharmacokinetic study of roxatidine acetate in chronic renal failure.
Lameire N; Rosenkranz B; Maass L; Brockmeier D
Drugs; 1988; 35 Suppl 3():48-52. PubMed ID: 2905249
[TBL] [Abstract][Full Text] [Related]
20. [Cefamandol: pharmacokinetics with normal and impaired renal function (author's transl)].
Höffler D; Moecke D; Sassmann M
Dtsch Med Wochenschr; 1978 Aug; 103(34):1334-8. PubMed ID: 679835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
